Abbott Laboratories (ABT) Stock After Recent Rebound Is There Still Value Left

Abbott Laboratories (ABT) is in focus after a rebound in its shares, prompting investors to reassess whether the latest moves signal fair value. The stock gained 6.5% over the past week and rose 9.9% over the last 30 days, but it remains down 24.2% year-to-date and 28.5% versus the last year. Simply Wall St’s valuation checks assign ABT a score of 5 out of 6 on undervaluation indicators, framing the renewed interest as potentially opportunity-driven. The article models intrinsic value using a two-stage discounted cash flow approach based on free cash flow to equity. With trailing twelve-month free cash flow of about $7.1 billion and projections of roughly $10.4 billion in 2028, the DCF estimates an intrinsic value of $141.15 per share and an implied discount of 33.3%.